Corporate
About ACI
Team
Scientific Advisory Board
Our Approach
ALPHA-1062
Alzheimer's Disease
Cognitive Impairment with Mild Traumatic Brain Injury
ALPHA-0602
Amyotrophic Lateral Sclerosis
ALPHA-0702 and ALPHA-0802 (GEMs)
Our Pipeline
Investors
Stock Info
News
Financials and Filings
Events & Presentations
Investor Relations Contact
Governance
Contact
Menu
Corporate
About ACI
Team
Scientific Advisory Board
Our Approach
ALPHA-1062
Alzheimer's Disease
Cognitive Impairment with Mild Traumatic Brain Injury
ALPHA-0602
Amyotrophic Lateral Sclerosis
ALPHA-0702 and ALPHA-0802 (GEMs)
Our Pipeline
Investors
Stock Info
News
Financials and Filings
Events & Presentations
Investor Relations Contact
Governance
Contact
Bringing Hope
to People Living with Neurodegenerative Diseases
Investor Presentation
Latest News Release
09.27.2023
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Read More
Treatments
Alzheimers: ALPHA-1062
A New Approach
Read More
Quick Links
About ACI
ALPHA-0602
Team
Contact
Latest News
View All
09.27.2023
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Read More
08.22.2023
Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update
Read More
View All
CSE: ACOG
15 min delay
Last
$0.24
Change
$0.00
Open
0.24
Vol
0
High
0.24
Low
0.24
Stock Information
